The platform versus product debate is a false dichotomy. A true platform is a durable factory or 'flywheel' that repeatedly generates new, valuable products over time. This model requires sufficient capital and a genuinely enabling technology, not just a collection of similar assets.

Selling a new chemistry platform to the conservative pharmaceutical industry is incredibly difficult. Value is only demonstrated when the novel chemistry is used to solve a specific, high-value biological problem that is intractable with conventional methods, thereby proving its unique power.

Industrial biotech startups often fail trying to scale cost-effectively. Since customers rarely pay a premium for sustainability alone, directly replacing a cheap petrochemical is a losing battle. A better strategy is to develop unique products with novel functionalities.

Experts advise platform technology founders to resist showcasing broad applicability. Instead, they should focus on specific use cases where they can generate compelling evidence, such as for a particular disease or drug modality. This builds credibility and creates a "beachhead" for future expansion.

To manage risk, Metaphor focuses its internal pipeline on known, validated biological mechanisms rather than pursuing novel biology. Their innovation lies in creating highly differentiated molecules for these proven targets—a chemistry and engineering challenge, not a biological discovery one.

To avoid being crushed by AI platform advancements, startups shouldn't compete directly with core models ('under the rock'). Instead, they should find a specific, underserved problem on the outer edge of what's newly possible, where deep user familiarity provides a defensible moat.

Radical AI learned from early customer feedback that success required deep vertical integration—from discovery to scaled manufacturing—in a single material class (alloys). A broad, horizontal approach across many materials was not viable.

Founders of platform technologies are often tempted to pursue many applications at once. A more effective strategy is to select and aggressively advance a single "beachhead program" to the clinic. This demonstrates the platform's value concretely, making it easier to attract funding and partners, while avoiding the dilution of resources.

For a platform company with wide-ranging technology, the key early struggle is focusing. It is critical to prioritize a single program to generate near-term data and change the cost of capital before realizing the platform's full potential.